ADC Therapeutics (ADCT) Long-Term Investments (2020 - 2024)

ADC Therapeutics (ADCT) has reported Long-Term Investments for 5 consecutive years, with $260000.0 the latest figure, recorded in Q2 2024.

• Quarterly Long-Term Investments fell 99.08% year-over-year to $260000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $260000.0 (down 99.08% YoY) and the FY2023 annual result came in at $1.6 million, down 78.37% from the prior year.
• Long-Term Investments eased to $260000.0 in Q2 2024 per ADCT's latest filing, from $930000.0 in the prior quarter.
• Over the last five years, Long-Term Investments for ADCT reached as high as $47.9 million in Q4 2020 and fell as low as $260000.0 in Q2 2024.
• A 5-year average of $27.2 million and a median of $29.5 million in 2023 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments retreated 18.25% — and 2024, when it tumbled 99.08%.
• Year by year, Long-Term Investments stood at $47.9 million in 2020, then plunged by 63.06% to $17.7 million in 2021, then slumped by 56.98% to $7.6 million in 2022, then sank by 78.37% to $1.6 million in 2023, then plunged by 84.21% to $260000.0 in 2024.
• According to Business Quant data, Long-Term Investments over the past three periods registered $260000.0, $930000.0, and $1.6 million for Q2 2024, Q1 2024, and Q4 2023 respectively.